PROBLEM TO BE SOLVED: To provide methods for treating or inhibiting progression of hepatic disorders.SOLUTION: A method comprises administering an effective amount of polyunsaturated substance to a patient in need of treatment of alcoholic or non alcoholic fatty liver disease, steatohepatitis, cirrhosis, hepatocellular carcinoma, cholelitiasis, obstructive jaundice or biliary tract diseases, where the polyunsaturated substance is chemically modified such that one or more bonds are stabilized against oxidation； and the polyunsaturated substance having one or more stabilized bonds or a metabolite thereof is incorporated into the patient's body following the administration. In some embodiments, the polyunsaturated substance is a fatty acid, fatty acid mimetic or fatty acid prodrug, and is stabilized at bis-allylic positions. In some embodiments, the stabilization at the bis-allylic position comprises one or more 13C atoms or one or more D atoms, and the level of the 13C atom or D atom is significantly above the naturally-occurring abundance level of the isotope.SELECTED DRAWING: Figure 1ACOPYRIGHT: (C)2017,JPO&INPIT【課題】肝障害の進行を治療又は阻害する方法の提供。【解決手段】有効量の多価不飽和物質を、アルコール性脂肪肝疾患、非アルコール性脂肪肝疾患、脂肪性肝炎、肝硬変、肝細胞癌、閉塞性黄疸、胆石症又は胆道疾患を有して治療を必要とする患者へ投与することを含み、ここで、多価不飽和物質は、１つ以上の結合が酸化に対して安定化されるように化学的に修飾されており；前記１つ以上の安定化された結合を含む多価不飽和物質又はその多価不飽和代謝物が、投与後に患者の体内に取り込まれることを含む方法。前記多価不飽和物質が、脂肪酸、脂肪酸模倣物又は脂肪酸プロドラッグであり、１つ以上のビス－アリル位で安定化される、方法。前記安定化がビス－アリル位において、１個以上の１３Ｃ原子又は１個以上のＤ原子を含み、１３Ｃ原子又はＤ原子が天然の同位体レベルより存在量が顕著に高い存在である、方法。【選択図】図１Ａ
